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Abstract
Fibroblast growth factor receptors (FGFRs) are activated by mutation and overexpressed in bladder cancers (BCs), and FGFR
inhibitors are currently being evaluated in clinical trials in BC patients. However, BC cells display marked heterogeneity in
their responses to FGFR inhibitors, and the biological mechanisms underlying this heterogeneity are not well defined. Here
we used a novel inhibitor of FGFRs 1–3 and RNAi to determine the effects of inhibiting FGFR1 or FGFR3 in a panel of human
BC cell lines. We observed that FGFR1 was expressed in BC cells that also expressed the ‘‘mesenchymal’’ markers ZEB1 and
vimentin, whereas FGFR3 expression was restricted to the E-cadherin- and p63-positive ‘‘epithelial’’ subset. Sensitivity to the
growth-inhibitory effects of BGJ-398 was also restricted to the ‘‘epithelial’’ BC cells and it correlated directly with FGFR3
mRNA levels but not with the presence of activating FGFR3 mutations. In contrast, BGJ-398 did not strongly inhibit
proliferation but did block invasion in the ‘‘mesenchymal’’ BC cells in vitro. Similarly, BGJ-398 did not inhibit primary tumor
growth but blocked the production of circulating tumor cells (CTCs) and the formation of lymph node and distant
metastases in mice bearing orthotopically implanted ‘‘mesenchymal’’ UM-UC3 cells. Together, our data demonstrate that
FGFR1 and FGFR3 have largely non-overlapping roles in regulating invasion/metastasis and proliferation in distinct
‘‘mesenchymal’’ and ‘‘epithelial’’ subsets of human BC cells. The results suggest that the tumor EMT phenotype will be an
important determinant of the biological effects of FGFR inhibitors in patients.
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Introduction
Bladder cancer (BC) is the fifth most common cancer in
Western countries. Bladder cancers can be divided into two major
subgroups that possess distinct pathological, clinical, and molec-
ular characteristics [1,2]. Most BCs (70%–80%) are low grade,
non-muscle invasive papillary (‘‘superficial’’) tumors (NMIBCs)
that rarely progress, so patients with this form of cancer have a very
good prognosis. On the other hand, patients with muscle-invasive
bladder cancers (MIBCs) have a much poorer prognosis (,50% 5-
year survival) [1,2]. MIBCs often progress to become metastatic,
and patients with metastatic disease have a dismal 5-year survival
rate of less than 5%. Consequently, identifying the molecular
mechanisms involved in BC invasion and metastasis and
identifying therapeutic strategies that target these processes are
very high priorities in ongoing research.
Fibroblast growth factor receptors (FGFRs) are very attractive
candidate targets in both subsets of BCs [3]. At least two thirds of
NMIBCs contain activating FGFR3 mutations that result in
ligand-independent receptor dimerization and constitutive down-
stream signal transduction [4,5,6,7], and in vitro studies have
established that FGFR inhibitors block proliferation in normal
urothelial cells that overexpress these receptors [8,9]. Although the
frequency of activating FGFR3 mutations in MIBCs is much lower
(,25%), many of them express high levels of FGFR3 and other
FGFRs [3,10,11]. In addition to promoting proliferation, FGFRs
have been implicated in the regulation of epithelial-to-mesenchy-
mal transition (EMT), invasion, and anchorage-independent
growth in BC cells [11].
BGJ-398 is a selective inhibitor of FGFRs 1, 2, and 3 that was
synthesized using a novel chemical approach [12]. It exhibits
IC50’s of approximately 5 nM against wild-type FGFRs and the
most common mutant form of FGFR3 that is expressed in BCs
(S249C) [12]. An initial characterization of the compound’s
growth inhibitory effects in a panel of 8 human BC cell lines
revealed marked heterogeneity in responses, where it displayed
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IC50’s of 5–30 nM in half of the cell lines and IC50’s of over 1 mM
in the other half [12]. The observed heterogeneity is consistent
with results obtained using a distinct chemical inhibitor [13], but
the molecular basis for this heterogeneity remains unclear. We
therefore initiated the present study to obtain a better un-
derstanding of the effects of FGFR inhibition in BC cells, with the
goal of identifying biological mechanisms and biomarkers that
could be used to prospectively identify FGFR-dependent tumors.
Our results reveal distinct, EMT-related roles for FGFR3 and
FGFR1 in driving proliferation and invasion that have important




BGJ-398 was generously provided by Novartis. For in vitro
studies, BGJ-398 was reconstituted in DMSO at a stock concen-
tration of 10 mmol/L and stored at 220uC. The BGJ-398 stock
was diluted in medium just prior to use so that the concentration of
DMSO never exceeded 0.1%. For in vivo studies, BGJ-398 was
dissolved in 10% Tween-80.
Tumor Cell Lines and Culture Conditions
Cell lines were obtained from the University of Texas MD
Anderson Cancer Center Bladder SPORE Tissue Bank, and their
identities were confirmed by DNA fingerprinting using the
AmpFlSTRH IdentifilerH Amplification (Applied Biosystems) or
AmpFlSTRH ProfilerH PCR Amplification (Applied Biosystems)
protocols. All cell lines were maintained as monolayers in modified
Eagle’s MEM supplemented with 10% fetal bovine serum,
vitamins, sodium pyruvate, L-glutamine, penicillin, streptomycin,
and nonessential amino acids at 37uC in a 5% CO2 incubator.
Animals
Female athymic nude mice (NCr-nu) were purchased from the
National Cancer Institute. The mice were housed under specific
pathogen-free conditions in the Animal Core Facility at The
University of Texas M. D. Anderson Cancer Center. The facility
has received approval from the American Association for
Accreditation of Laboratory Animal Care and in agreement with
current regulations and standards of the U.S. Department of
Health and Human Services, the U.S. Department of Agriculture,
and the NIH. The mice used in these experiments were 6 to 8
weeks old.
FGFR3 Mutation Analyses
DNA was isolated from BC cell lines using a genomic DNA
extraction kit (Qiagen). PCR was performed to amplify exons 7
and 10 using AmpliTaq Gold DNA polymerase (Applied
Biosystems) and the primers 59-CGGCAGTGGCGGTGGTG-
GTG-39(sense) and 59-AGCACCGCCGTCTGGTT GGC-39
(antisense) for exon 7 (23) and 59-CCTCAACGCC-
CATGTCTTT-39 (sense) and 59-AGGCAGCTCA-
GAACCTGGTA-39 (antisense) for exon 10 (purchased from
Sigma Genosys). The following cycling variables were used: 95uC
for 10 min, then 35 cycles of 95uC for 30 s, 65uC (exon 7) or 58uC
(exon 10) for 30 s, and 72uC for 30 s, followed by a final
incubation at 72uC for 10 min (23). Unincorporated primers and
deoxynucleotides were removed using shrimp alkaline phosphatase
and exonuclease I (U.S. Biochemical). Products were analyzed by
Big Dye Terminator Cycle Sequencing (Applied Biosystems), and
the data were analyzed with Sequencing Analysis 3.0 software
(Applied Biosystems).
RNAi-mediated Knockdown of FGFR3, FGFR1 or bFGF
UM-UC14 and RT4 were transfected with small interfering
RNAs (siRNAs) targeting FGFR3 and FGFR1 using Oligofec-
tamine (Invitrogen) according to the manufacturer’s instructions.
Targeted oligonucleotides (sequence) and a non-targeting control
were purchased from Ambion. Total RNA was collected 48
hours after transfection and analyzed by RT-PCR to confirm
target knockdown. In parallel, siRNA transfected cells were
harvested at 48 hours and analyzed using the cell proliferation
and cell cycle assays described below. UM-UC3 and UM-UC13
were transduced with lentiviral short hairpin RNAs (shRNA-
s)(Open Biosystems). Cells were continuously cultured for 5,7
days in 10% MEM containing puromycin. Total RNA was
collected after selection and analyzed by RT-PCR to confirm
target knockdown. Stable knockdown cells were maintained in
puromycin and used in the MTT and Boyden chamber
invasion assays described below.
Immunoblotting Analyses
Cells were harvested at ,75% to 85% confluence and lysed.
Protein concentrations were measured using the Bradford assay
(Bio-Rad Laboratories, Hercules, CA). Lysates were boiled in
sample buffer (62.5 mmol/L Tris-HCl (pH 6.8), 10% (w/v)
glycerol, 100 mmol/L DTT, 2.3% SDS, 0.002% bromophenol
blue) for 5 minutes and cooled on ice for 5 minutes. Samples
were separated on 8% or 12% SDS-PAGE gels at 110 V in
electrophoresis buffer (25 mmol/L Tris-HCl (pH 8.3),
192 mmol/L glycine, 0.1% SDS) and then electrophoretically
transferred onto methanol-prewetted polyvinylidene difluoride
(PVDF) membranes in transfer buffer (25 mmol/L Tris-HCl,
192 mmol/L glycine, 20% methanol) for 1 hour at 100 mV.
The membranes were incubated in blocking buffer (TBS:
10 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 5% nonfat
milk) for 1 hour at room temperature while shaking and then
rinsed once briefly with TBS-T (TBS containing 0.1% Tween-
20). The membranes were incubated with primary antibodies
diluted 1:1000 in blocking buffer overnight, washed, and then
incubated with second antibodies (anti-mouse or anti-rabbit
immunoglobulin, horseradish peroxidase–linked F(ab)2 fragment
from mouse) diluted 1:8,000 in blocking buffer for 1 hour at
room temperature while shaking. Immunoreactive proteins were
detected using enhanced chemiluminescence (Amersham Bios-
ciences, Piscataway, NJ) according to the manufacturer’s
instructions.
Gene Expression Profiling
Gene expression profiling was performed on a panel of 30
human BC cell lines using the Illumina platform. For each cell
line, mRNA was generated from a single log-phase culture. RNA
purity and integrity were measured using a NanoDrop ND-1000
and an Agilent Bioanalyzer, and only high quality RNA was used
for cRNA amplification. Biotin-labeled cRNA was prepared using
the Illumina RNA amplification kit (Ambion, Inc, Austin, TX),
and amplified cRNA was hybridized to Illumina HT12 V4 chips
(Illumina, Inc., San Diego, CA). After they were washed, the slides
were scanned with IScan (Illumina, Inc.). Signal intensities were
quantified with GenomeStudio (Illumina, Inc.), and quantile
normalization was used to normalize the data. BRB ArrayTools
version 4.2 developed by National Cancer Institute [14] was used
to analyze the data. To observe the expression patterns of
differentially expressed genes, specific gene expression values,
adjusted to a mean of zero, were used for clustering with Cluster
and TreeView [15].
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Figure 1. Expression of FGFR1, FGFR3, and bFGF in distinct subsets of human BC cell lines. A. Correlation of FGFR1 and FGFR3 with
canonical EMT markers. mRNA levels were measured using whole genome mRNA expression profiling (Illumina platform). The heat map depicts the
expression of FGFR1, FGFR3, FGF2 (bFGF), p63 (TP63), E-cadherin (CDH1), Slug (SNAI2), and vimentin. B. Quantitative analysis of EMT marker
expression. Relative levels of the ‘‘epithelial’’ markers E-cadherin (CDH1) and p63, and the ‘‘mesenchymal’ markers ZEB1 and vimentin were measured
by quantitative real-time RT-PCR.
doi:10.1371/journal.pone.0057284.g001
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Figure 2. Relationship between FGFR/bFGF expression and EMT. A. Expression of FGFRs 1–4 and bFGF in relationship to E-cadherin
expression. The relative mRNA levels were measured by quantitative real-time RT-PCR. The cell lines in each panel are organized by relative E-
cadherin expression (low to high, from left to right; see Fig. 1B). B. Scatterplots depicting the relationships between FGFR1, bFGF, FGFR3, and EMT
marker expression. Nonparametric correlation analyses were used to evaluate the relationships between FGFR3 and E-cadherin (CDH1) expression,
FGFR1 and ZEB1 expression, bFGF and ZEB1 expression, and bFGF and FGFR1 expression. Correlation coefficients and p values are indicated on the
figure.
doi:10.1371/journal.pone.0057284.g002
FGFR Inhibition in Bladder Cancer Cells
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e57284
MTT Assays
Cells (56103) were plated in 96-well plates and allowed to
adhere for 24 hours before they were incubated with or without
increasing concentrations of BGJ-398 for 48 h or 5 days. MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays
were used to measure relative cell numbers based on conversion of
MTT to formazan in viable cells. Fifty ml MTT dissolved in PBS
(50 mg/ml) was added to each well and plates were incubated for 3
hours. The medium was then removed and 100 ml DMSO was
added to each well to lyse cells and solubilize the formazan. A
standard micro-plate reader was used to determine the absorbance
(600 nm). Each experimental data point represents average values
obtained from six replicates and each experiment was performed
at least twice.
Real-time Reverse Transcriptase PCR Analyses
Cells were harvested at 75% to 85% confluence and total RNA
was isolated using mirVANATM miRNA Isolation Kit (Ambion,
Life Science, CA). FGFRs and other genes of interests were
analyzed by Taqman-based real-time PCR (ABI PRISM 7500;
Applied Biosystems). The comparative CT method was used to
determine relative gene expression for each target gene; the
cyclophilin A gene was used as internal control to normalized the
amount of amplifiable RNA. Taqman primers was purchased
from the manufacture (Applied Biosystem, CA) as follows: E-
cadherin; Hs00170423_m1, TP63; Hs00978343_m1, ZEB1;
Hs00232783_m1, Vimentin; Hs00185584_m1, FGFR1;
Hs00915142_m1, FGFR2; Hs01552926_m1, FGFR3;
Hs00179829_m1, FGFR4; Hs01106908_m1, bFGF;
Hs00266645_m.
Cell Cycle Analyses
Cells were plated in 6-well plates and maintained in 10% FBS
MEM for 24 hours. Cells were then exposed to various
concentrations of BGJ-398 for 48 hours or grown another 24
hours (reaching,75% to 85% confluence) to analyze the effects of
FGFR3 or FGFR1 knockdown. Cells were harvested by
trypsinization and pelleted by centrifugation. The pellets were
then resuspended in PBS containing 50 mg/mL propidium iodide,
0.1% Triton X-100, and 0.1% sodium citrate. Propidium iodide
fluorescence was measured by fluorescence-activated cell sorting
(FL-3 channel, Becton Dickinson, Mountain View, CA) using the
instrument’s cycle analysis software.
Boyden Chamber Invasion Assays
Invasion chambers containing Matrigel-coated polyethylene
terephthalate membranes with 8 mm pores were purchased from
BD Science in a 24-well plate format. Cells (2.56105) were
released from tissue culture flasks using EDTA (1 mmol/L),
centrifuged, suspended in a serum free medium and placed in the
upper compartments of invasion chambers. Thirty percent fetal
bovine serum medium was placed in the lower compartments as
a chemoattractant and invasion assays were carried out for 48 h.
Each cell line was plated in triplicate. To examine cell invasion
after exposure to BGJ-398, cells that had not invaded were
removed and the cells on the lower surface of the filter were
stained with Diff-Quick (American Scientific Products, McGaw
Park, IL). Invasive activity was measured by counting the cells that
had migrated to the lower side of the filter. To evaluate invasion
after silencing FGFR1 or bFGF, membranes were removed after
incubation for 48 hours at 37uC and stained in propidium iodide
(Sigma-Aldrich) without removing cells from the upper surfaces of
the membranes. The filters were mounted on glass slides and
analyzed by confocal microscopy at 1006 magnification. The
planes of focus were adjusted so that the cells that had not invaded
could be distinguished from the invaded cells and counted in 8
independent fields. Invasive activity was measured by calculating
ratios of invaded to noninvaded cells.
Archorage Independent Growth Assay
UM-UC3 and UM-UC13 wild type or bFGF/FGFR1 silenced
cells were plated at 16104 cells per well in 6-well-plates
supplemented with 10% FBS MEM containing 0.6% agar. Cells
were allowed to grow for 2 weeks. Images were acquired using an
Olympus IX inverted-phase contrast microscope. The total
numbers of colonies per random view (1006) and the average
diameter of colonies per random view (1006) were determined
using a SliderBook image analyzer.
Orthotopic Xenograft Experiments
The human BC cell line UM-UC-3 was transduced with
a lentiviral vector encoding luciferase (luc) and red fluorescent
protein (RFP; mCherry) as described previously [16]. After stable
transduction with the luc-RFP reporter, cells were sorted by
Fluorescence Activated Cell Sorting (FACS) using an Influx High-
Speed sorter (BD Biosciences). Luciferase activity was quantified
in vitro using D-luciferin (150 mg/mL) and the IVIS biolumines-
cence system (Xenogen Co.). To produce tumors in nude mice,
subconfluent cultures of labeled UM-UC3 were lifted with trypsin,
mixed with 10% FBS MEM, centrifuged at 1,200 rpm for 5 min,
washed in PBS, and resuspended in HBSS. Cells were then
injected orthotopically into the bladder wall at a concentration of
56105/50 mL using a lower laparotomy. Mice bearing metastases
were euthanized 5 to 8 weeks after tumor cell injection, the lymph
node and distant metastases were excised, cut into small pieces
using scalpels, exposed to 1% trypsin for 20 minutes, centrifuged
(1,200 rpm for 5 min), and cultured in 10% supplemented MEM.
After FACS sorting, the recycled cells were subconfluently
cultured and reinjected at a concentration of 26105/50 mL HBSS
as described above. Thus, tumor cell recycling was performed
three times in order to select a highly metastatic UM-UC3
subpopulation which develops metastases in ,75% of mice. For
our therapy experiment, we injected the 4th cycle of recycled UM-
UC3 at a concentration of 26105/50 mL. Mice with detectable
tumor growth at the time of the first imaging (5 days after
injection) were randomized into two groups (n = 7/group).
In vivo Bioluminescence Imaging
Bioluminescence imaging was conducted on an IVIS 100
imaging system with Living Image software (Xenogen) as de-
scribed elsewhere [16]. In brief, animals were anesthetized before
imaging with a 2.5% isoflurane/air mixture and injected s.c. with
15 mg/mL of luciferin potassium salt in PBS at a dose of 150 mg/
kg body weight. A digital gray-scale animal image was acquired
and a pseudocolored image was overlaid representing the spatial
distribution of detected photons emerging from active luciferase.
Signal intensity was quantified as the sum of all detected photons
within the region of interest per second, separately counting each
primary tumor and each metastatic site.
Collection of Primary Tumors and Circulating Tumor Cells
(CTCs)
Forty days after injection, when animals in the control group
became moribund, mice were anesthetized with isoflurane as
described above. To measure the number of CTCs, the maximal
amount of blood (600–1200 ml) was collected by cardiac puncture
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Figure 3. FGFR3 levels predict sensitivity to BGJ-398-induced cell cycle arrest. A. Effects of BGJ-398 on cell proliferation in the drug-
sensitive cells. In the left panel, cells were incubated for 48 h in the presence of the indicated concentrations of BGJ-398 and cell growth was
measured by MTT reduction. Mean 6 SEM, n = 6. In the center and right panels, UM-UC14 or RT4 cells were incubated with the indicated
concentrations of BGJ-398 and the percentages of cells within each cell cycle quadrant were quantified by propidium iodide staining and FACS
analysis. Mean 6 SEM, n= 3. B. Sensitivity to the anti-proliferative effects of BGJ-398 correlates with FGFR3 expression but not with the presence of
activating FGFR3 mutations. The level of growth inhibition observed after 48 h exposure to 1 mM BGJ-398 (as measured in MTT assays) was correlated
with the relative level of FGFR3 (left panel) or FGFR1 (right panel) mRNA expression in a panel of 17 human BC cell lines.. C. Effects of FGFR3
knockdown on cell proliferation. Left panel: UM-UC14 or RT4 cells were transiently transfected with either non-targeting (NT) or FGFR3-specific siRNAs
and cell growth was measured at 48 h by MTT reduction. Mean 6 SEM, n= 6. Center and right panels: UM-UC14 or RT4 cells were transiently
transfected with either non-targeting (NT) or FGFR3-specific siRNAs and percentages of cells within each phase of the cell cycle were quantified by
propidium iodide staining and FACS analysis. Mean6 SEM, n = 3. Lower panel: the efficiency of FGFR3 silencing was measured by quantitative RT-PCR
and immunoblotting.
doi:10.1371/journal.pone.0057284.g003
FGFR Inhibition in Bladder Cancer Cells
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e57284
Figure 4. FGFR1 selectively regulates invasion in ‘‘mesenchymal’’ bladder cancer cells. A. Left panel: effects of BGJ-398 on cell growth in
two ‘‘mesenchymal’ (UM-UC3, UM-UC13) and two ‘‘epithelial’’ (UM-UC6, UM-UC9) cell lines that were found to be resistant to the anti-proliferative
effects of the drug. Growth inhibition was measured at 48 h by MTT reduction. Mean 6 SEM, n = 6. Center panel: concentration-dependent effects of
BGJ-398 on invasion in the UM-UC3 and UM-UC13 cells. Invasion was measured using modified Boyden chambers and standard light microscopy as
described in Materials and Methods. Mean 6 SEM, n = 3. Right panel: effects of BGJ-398 on invasion in the UM-UC6 and UM-UC9 cells. Note that the
FGFR Inhibition in Bladder Cancer Cells
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using 1 ml syringe, 22 gauge needle, and heparin-coated collection
tubes as described previously [17]. Mice were then euthanized
with carbon monoxide. Tumors were excised, and samples were
either formalin fixed and embedded in paraffin, embedded in
OCT (Miles, Inc), or frozen rapidly in liquid nitrogen and stored
at 280uC for RNA and protein extraction. For further blood
processing, red blood cells were lysed twice for 5 min with 1 ml
ACK lysis buffer (Invitrogen), and centrifuged for 5 min at
1200 rpm in Eppendorf tubes. The pellet was finally lysed and
further processed for total RNA isolation using the mirVANATM
miRNA Isolation kit (Ambion, Life Science). For Real-time PCR
analysis, PCR technology (Step One; Applied Biosystems) was
used together with TaqManH Gene Expression Assays (Applied
Biosystems). Absolute quantification was used to generate cycle
threshold (CT) values for human specific HLA-C primer
(Hs00740298_g1) for each sample. RT-PCR analysis of the blood
samples (in triplicates) was run together with standard isolates (0, 2,
20, 200, 2000, and 20,000 UM-UC3 cells in 100 ml mouse blood).
CT values of the standards were used to create a standard curve
for UM-UC3 CTC, and the number of CTCs of each blood
sample was calculated accordingly.
Results
Relationship between E-cadherin and bFGF/FGFR
Expression in UC Cells
We analyzed the expression of the 4 FGFRs and the dominant
cancer-associated ligand (FGF-2/basic FGF) at the mRNA level in
a panel of 30 UC cell lines by whole genome expression profiling
(Illumina platform). Expression of FGFR3 correlated directly with
expression of p63 [18,19] and E-cadherin [20](Fig. 1A), indicating
that FGFR3 is expressed by the ‘‘epithelial’’ subset of BC cells.
Conversely, the expression of FGFR1 correlated more directly
with the ‘‘mesenchymal’’ marker vimentin (Fig. 1A). We used
quantitative real-time reverse transcriptase PCR (RT-PCR) to
more accurately define the patterns of expression of ‘‘epithelial’’
and ‘‘mesenchymal’’ markers across the panel of cell lines. The
results are displayed in Figure 1B, where we organized the BC cell
lines in all of the panels according to their relative expression of
the canonical ‘‘epithelial’’ marker E-cadherin (Fig. 1B, upper left
panel) [20]. The expression of E-cadherin correlated directly with
expression of p63 and inversely with expression of ZEB1 and
vimentin, demonstrating that the ‘‘epithelial’’ and ‘‘mesenchymal’’
markers are expressed in a largely non-overlapping fashion in the
BC lines (Fig. 1B). Only two of the cell lines (1A6 and UM-UC18)
co-expressed ‘‘epithelial’’ and ‘‘mesenchymal’’ markers (Fig. 1B).
We then measured expression of FGFRs 1–4 and FGF-2 by
quantitative RT-PCR (Fig. 2A). Confirming the gene expression
profiling results, FGFR1 was expressed primarily by cells within
the ‘‘mesenchymal’’ subset (UM-UC3, UM-UC13, T24, BV and
UC12)(Fig. 2A top left), whereas FGFR3 expression was concen-
trated within the ‘‘epithelial’’ cells, with RT4 having the highest
expression followed by UM-UC14, SW780 and RT112 (Fig. 2A,
top right). FGFR2 also appeared to be somewhat enriched in the
‘‘epithelial’’ and FGFR4 in the ‘‘mesenchymal’’ cells, respectively,
but their levels of expression were much lower than the levels of
FGFR3 or FGFR1 (mean of 36 cycles versus 30 cycles of PCR),
consistent with previous findings [10]. Finally, the ‘‘mesenchymal’’
cells expressed higher levels of FGF2 (bFGF) than did the
‘‘epithelial’’ cells (Fig. 2A). We confirmed that FGFR3 expression
was enriched in the ‘‘epithelial’’ and FGFR1 and bFGF expression
was enriched in the ‘‘mesenchymal’’ cell lines at the protein level
by immunoblotting (Figure S1). Using nonparametric correlation
analyses, we confirmed that FGFR3 expression correlated strongly
and directly with expression of E-cadherin (Spearman r= 0.8155,
p,0.0001, Fig. 2B) and inversely with expression of the
‘‘mesenchymal’’ markers (Fig. S2). Conversely, expression of
FGFR1 and bFGF strongly and directly correlated with expression
of ZEB1 (Spearman r= 0.799, p = 0.0001 for FGFR1 and
r = 0.6198, p = 0.008 for bFGF) (Fig. 2B). In addition, bFGF and
FGFR1 expression correlated directly with each other as expected
(Fig. 2B). We then examined whether the observed differences in
mRNA expression translated into differential expression at the
protein level in a subset of the cell lines by immunoblotting. We
found that FGFR3 but not FGFR1 was expressed in the epithelial
UM-UC14, RT4 and RT112 cells, whereas FGFR1 but not
FGFR3 was expressed in mesenchymal UM-UC3, UM-UC12 and
UM-UC13. FGF-2 was expressed in all 6 cell lines, but the
mesenchymal cells expressed more FGF-2 than the epithelial’’ cells
did. Together, these data support the idea that FGFR3 and
bFGF/FGFR1 probably function in non-overlapping epithelial
and mesenchymal subsets of BC cells.
Effects of BGJ-398 on Cell Proliferation
Previous studies concluded that FGFR inhibitors block pro-
liferation in some human BC cells in vitro [12,13]. We therefore
tested the effects of BGJ-398 on proliferation in 17 BC cell lines to
characterize the extent of the heterogeneity in drug sensitivity. We
incubated the cells with increasing concentrations of BGJ-398 for
48 hours and measured cytotoxicity and growth arrest using MTT
assays. We identified 5 cell lines (UM-UC14, SW780, RT4,
RT112 and UM-UC1) that were drug-sensitive as defined by
$50% growth inhibition at drug concentrations of 1 mmol/L or
lower (Fig. 3A left panel and data not shown). To determine the
relative contributions of growth arrest and cell death to these
effects, we exposed the UM-UC14 and RT4 cells to increasing
concentrations of BGJ-398 for 48 hours and directly measured cell
cycle arrest and apoptosis by propidium iodide staining and FACS
analysis. In both cell lines increasing concentrations of BGJ-398
produced increases in the percentages of cells in the G1 phase and
parallel decreases in the percentages of cells in S phase.
Specifically, the percentages of cells within the G1 phase increased
from 47.5% and 54% to 74.2% and 69.1%, while percentages of
cells in S phase decreased from 33.5% and 25% to 2.7% and 8.8%
in the BGJ-398-exposed UM-UC14 and RT4 cells, respectively
(Fig. 3A). On the other hand, BGJ-398 did not induce apoptosis in
either cell line at concentrations below 10 mM (data not shown).
Therefore, BGJ-398 exerts primarily cytostatic effects on BC cells
in vitro.
We then examined the relationship between BGJ-398 sensitivity
and the presence of activating FGFR3 mutations. Using exon
sequencing we identified 5 cell lines within our panel that
contained activating FGFR3 mutations (UM-UC6, UM-UC14,
UM-UC15, UM-UC16 and UM-UC17) (Fig. S3). Strikingly, only
drug had no effect on invasion in either cell line. B. Stable knockdown of FGFR1 or bFGF in cells transduced with lentiviral shRNAs. Relative mRNA
levels were measured by quantititative real-time RT-PCR and protein levels were measured by immunoblotting. C. Effects of FGFR1 or bFGF
knockdown on invasion. Left panels: percentages of cells that invaded through Matrigel in modified Boyden chambers were quantified by propidium
iodide staining and confocal microscopy. The right panels display representative confocal images where the nuclei of the cells that invaded are
pseudo-colored blue and the cells that did not invade are depicted in red.
doi:10.1371/journal.pone.0057284.g004
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Figure 5. Effects of BGJ-398 on UM-UC3 primary tumor growth and metastasis. A. Effects on primary tumor growth. Luciferase-labelled,
orthotopically recycled UM-UC3 cells were implanted into the bladders of nude mice, and tumors were allowed to grow for 8 days prior to initiating
therapy with BGJ-398 (daily via oral gavage). Tumor growth was measured biweekly by luciferase imaging. Mean6 SEM from 6 (control) or 7 (treated)
mice per group. B. Effects on metastasis. Whole animal metastatic burdens were determined non-invasively by luciferase imaging. Mean6 SEM, n = 6
(control mice) or 7 (treated mice). C. Representative whole body luciferase images taken just prior to the initiation of therapy and at the conclusion of
the experiment. D. Effects of BGJ-398 on CTC production. CTC numbers were estimated by measuring human HLA levels in isolated whole blood by
quantitative PCR; cell numbers were determined using a UM-UC3 standard curve. The scatterplot displays the results obtained from each animal; the
lines denote the mean values for each group.
doi:10.1371/journal.pone.0057284.g005
FGFR Inhibition in Bladder Cancer Cells
PLOS ONE | www.plosone.org 9 February 2013 | Volume 8 | Issue 2 | e57284
one of the FGFR3-mutant cell lines (UM-UC14) was also BGJ-398
sensitive. On the other hand, we observed a good correlation
between FGFR3 mRNA expression and drug sensitivity (Spear-
man r = 0.7247 p=0.01) (Fig. 3B left panel), whereas there was no
correlation between sensitivity to BGJ-398 and FGFR1 expression
(Spearman r=20.2931 p=0.2536) (Fig. 3B right panel).
Given the non-overlapping patterns of FGFR1 and FGFR3
expression, the results suggested that FGFR3 plays a more
important role than FGFR1 in driving proliferation human BC
cells. To more directly test this hypothesis, we used RNAi to knock
down FGFR1 or FGFR3 in the BGJ-398-sensitive UM-UC14 and
RT4 cells and measured the effects on cell proliferation using
MTT assays. Quantitative RT-PCR revealed knockdown efficien-
cies of 50% and over 80% in the RT4 and UM-UC14 cells
transfected with FGFR3-specific siRNAs, respectively compared
with cells transfected with the non-specific siRNA control, and
these results were also confirmed at the protein level by
immunoblotting (Fig. 3C lower panel). The corresponding effects
on cell proliferation were very similar, in that proliferation was
reduced by almost 50% in the RT4 cells and by over 80% in UM-
UC14 transfected with the FGFR3 siRNA (Fig. 3C left panel). Cell
cycle analyses confirmed that FGFR3 knockdown increased the
percentages of cells in the G1 phase and decreased the fractions of
cells in S phase (Fig. 3C center/right panels), consistent with the
MTT results and the previously observed effects of BGJ-398 [12].
In contrast, knockdown of FGFR1 had no significant effect on
proliferation (Fig. S4).
Effects of BGJ-398 on Invasion
Although the ‘‘mesenchymal’’ UM-UC3 and UM-UC13 cells
expressed relatively high levels of FGFR1, they were resistant to
the anti-proliferative effects of BGJ-398 (Fig. 4A left panel).
Because invasion, migration, and metastasis are characteristic
features of ‘‘mesenchymal’’ tumor cells [20], we examined the
effects of BGJ-398 on invasion in the UM-UC3 and UM-UC13
cells, using two ‘‘epithelial’’, BGJ-398-resistant cell lines (UM-UC6
and UM-UC9) as controls. We exposed cells to increasing
concentrations of BGJ-398 and measured invasion using modified
Boyden chambers. BGJ-398 strongly inhibited invasion in the
UM-UC3 and UM-UC13 cells in a concentration-dependent
manner, whereas it had no effects on invasion in the ‘‘epithelial’’
UM-UC6 and UM-UC9 cells (Fig. 4A center/right panels).
To more directly examine the involvement of FGFR1 and
bFGF in the regulation of invasion, we stably silenced their
expression in the UM-UC3 and UM-UC13 cells using lentiviral
shRNAs, and we used quantitative RT-PCR analyses to confirm
that silencing produced over 75% knockdown in all cases, and we
confirmed that these effects resulted in reduced protein expression
by immunoblotting (Fig. 4B). We then quantified the effects of
knockdown on invasion using modified Boyden chambers and
confocal microscopy. In the UM-UC3 background the percentage
of invading cells was reduced from 85% in the parental cells or
cells transduced with a control lentiviral construct to 54.5% in
bFGF KD cells (P = 0.0029) and 63.8% in FGFR1 KD cells
(P = 0.0038). Similarly, in the UM-UC13 background, the levels of
invasion were reduced from 82% in parental cells or cells
transduced with the non-targeting lentivirus to 64.8% in the
bFGF KD cells (P = 0.0146) and 52.4% in FGFR1 KD cells
(P = 0.0018) (Fig. 4C). Together, the data confirm that bFGF and
FGFR1 both promote invasion in ‘‘mesenchymal’’ BC cells.
Our observation that FGFR inhibition blocked invasion without
affecting proliferation in the cells that express high levels of
FGFR1 seemed to contradict previous work implicating FGFR1 in
the regulation of cell proliferation [10,11]. We therefore
performed additional experiments to determine whether FGFR1
inhibition produced effects on growth that become more obvious
in longer-term assays. Consistent with this idea, knockdown of
FGFR1 in UM-UC3 or either bFGF or FGFR1 in UM-UC13
partially inhibited cell growth in 5-day MTT assays (Fig. S5A) and
assays that measure colony formation in soft agar (Fig. S5B).
Effects of BGJ-398 on Tumor Growth and Metastasis
Although in vitro models are excellent tools for studying
molecular mechanisms, the process of cancer metastasis is
regulated by tumor-stromal interactions that cannot be modeled
well in vitro. Therefore, in order to better define the effects of
BGJ-398 on primary tumor growth versus metastasis in ‘‘mesen-
chymal’’ BC cells, we first isolated a highly metastatic form of UM-
UC3 using orthotopic ‘‘recycling’’ in nude mice [21]. We
transduced the cells with a lentiviral vector encoding luciferase
and red fluorescent protein (RFP), which enabled us to monitor
primary tumor growth and metastasis non-invasively by luciferase
imaging and to isolate circulating tumor cells (CTCs) by cell
sorting. After 3 rounds of recycling, the UM-UC3 cells formed
orthotopic tumors in 100% of mice and consistently produced
metastases to lymph nodes, lungs, and bone in over 70% of mice.
We then implanted 200,000 of the recycled UM-UC3 cells
orthotopically in nude mice and initiated therapy with BGJ-398 or
vehicle (via oral gavage) once primary tumors were well
established (on day 8), monitoring tumor growth and metastasis
biweekly by IVIS imaging (Fig. 5). Interestingly, primary tumors in
the mice treated with BGJ-398 appeared to grow slightly faster
than controls, although the differences in growth rates were not
statistically significant (Fig. 5A: P.0.05). In contrast, BGJ-398
strongly inhibited the development of CTCs and metastases.
Specifically, 5 out of 7 mice within the control group developed
lymph node metastasis by day 15, and two of these subsequently
developed bone and lung metastasis at day 36 (Fig. 5C right lower
panel). However, we detected only 1 lymph node metastasis in the
7 animals within the BGJ-398 treatment group. When we
quantified total metastatic burden using luciferase imaging, the
differences between the vehicle and BGJ-398 treatment groups
were highly significant (Fig. 5B,C: p = 0.0078). Finally, we
quantified the numbers of circulating tumor cells in the mice at
the time of sacrifice on day 40 by measuring human HLA-C levels
in whole peripheral blood by quantitative PCR. CTC numbers
within the control group ranged from 325 to 336,008 cells
(mean=158,977), whereas CTC numbers in the treated group
ranged from 160 to 370 (mean= 243.6)(Fig. 5D: p,0.01).
Together, the results demonstrate that BGJ-398 had no inhibitory
effect on the growth of UM-UC3 primary tumors but did block
tumor cell extravasation into the vasculature (as measured by
CTC production) and metastasis.
Discussion
The prevalence of activating FGFR3 mutations [5,7,22] and
FGFR-1 [10] and -3 [3,23] overexpression in BCs, coupled with
the fact that the mutant forms of FGFR3 drive cell proliferation
[9,24], makes FGFR inhibitors among the most attractive
candidates for clinical development [25]. However, it is clear
from the results of the preclinical studies that have been published
to date that human BC cells display marked heterogeneity in their
sensitivities to selective and non-selective FGFR inhibitors
[13,26,27,28], which could pose significant challenges to the
identification of the appropriate subset(s) of BC patients who will
benefit most from FGFR-directed therapy. Based on previous
experience in other solid tumors, it seemed likely that the presence
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of activating FGFR3 mutations identifies FGFR3-dependent BC
cells. It also seemed likely that overexpression of either FGFR-1 or
FGFR-3 would be linked to FGFR-1 or -3 dependency,
respectively. However, our results demonstrate that the presence
of an activating FGFR3 mutation does not predict sensitivity to
BGJ-398 in established human BC cell lines. Specifically, although
some of the BC cell lines that contain activating FGFR3 mutations
were highly sensitive to BGJ-398 and other FGFR inhibitors (UM-
UC14, 97-7, and MGHU3) [9,13,24,26,27,28], several other
FGFR3-mutant lines were not (UM-UC6, UM-UC15, UM-
UC16, UM-UC17, 94-10, 97-18, J82) [13,27], and some FGFR3
wild-type cell lines were just as sensitive to BGJ-398 and the other
inhibitors as the most sensitive FGFR3 mutant cells (UM-UC1,
RT4, RT112, and SW780) [13,28]. On the other hand, sensitivity
to BGJ-398 did correlate closely with FGFR3 mRNA levels (Fig. 3)
[13]. Importantly, the cell lines that expressed the highest levels of
FGFR1 expressed low levels of FGFR3 and were all relatively
resistant to BGJ-398-induced growth arrest when the effects of the
drug were measured early (48–72 h), strongly suggesting that
FGFR3 is a more important driver of BC cell proliferation than
FGFR1. Our data also demonstrate that the effects of BGJ-398 are
largely cytostatic (rather than cytotoxic), so clinical ‘‘responses’’
may not be associated with tumor regression, and in future studies
we plan to investigate whether FGFR3 inhibition can promote the
cytotoxic effects of conventional chemotherapy and/or other
investigational agents. Within this context, it is worth noting that
all of the available human BC cell lines are derived from muscle-
invasive tumors (with the possible exception of RT4), and it seems
likely that muscle-invasive BCs that gave rise to the FGFR
inhibitor-resistant, FGFR3 mutant cell lines had progressed
beyond the point where mutant FGFR3 was essential to maintain
proliferation and/or survival. Thus, we suspect that the preclinical
data underestimate the potential impact of FGFR3-based therapy
in patients with low-grade, non-muscle invasive FGFR3-mutant
cancers.
Although our results indicate that FGFR1 plays a less important
role than FGFR3 in driving BC tumor cell proliferation, they also
strongly suggest that FGFR1 plays crucial roles in invasion and
metastasis. Inhibition of FGFR signaling with either BGJ-398 or
FGFR1 knockdown resulted in strong suppression of invasion
in vitro, and BGJ-398 blocked CTC production and metastasis
(without inhibiting primary tumor growth) in mice inoculated with
orthotopic, FGFR1-positive UM-UC3 tumors in vivo (Fig. 5). On
the surface our conclusions may seem to contradict previous work
implicating FGFR1 in tumor cell proliferation in vitro and in
primary tumor growth in vivo, especially because some of the
experiments employed the same UM-UC3 cell line used here [10].
However, we were able to replicate the effects of FGFR1
knockdown on proliferation in long-term MTT assays and soft
agar colony formation, and our conclusion that FGFR1 inhibition
does not attenuate primary tumor growth is based on BGJ-398
therapy in established UM-UC3 tumors rather than on experi-
ments with cells stably transduced with an FGFR1 shRNA (where
FGFR1 would not be available for tumor establishment), so we are
confident that the results of the two studies are consistent with
each other. Perhaps a more important question is why inhibition
of FGFR3 has stronger effects on proliferation than inhibition of
FGFR1, since the effects of both have been clearly linked to
inhibition of ERK signaling [10,11,27,28]. We speculate that the
differential effects are related to the very distinct epithelial versus
mesenchymal biological phenotypes of the FGFR3- versus
FGFR1-positive cells and that the ‘‘epithelial’’ cells may be more
dependent on autocrine growth factors for proliferation, a conclu-
sion that is consistent with our previous work with inhibitors of the
EGF receptor [29,30]. Clinically, some non-muscle invasive
tumors progress to become muscle-invasive and metastatic. If
appropriate biomarkers (possibly including FGFR1 and EMT
marker expression) can be identified, it is conceivable that these
potentially lethal non-muscle invasive tumors could be controlled
with FGFR1 inhibitor-based chemoprevention strategies.
Finally, our data show that FGFR3 and FGFR1 are expressed
by the ‘‘epithelial’’ and ‘‘mesenchymal’’ subsets of bladder cancer
cells, respectively. The strong associations suggested to us that
direct cause-effect relationships might exist between them, and we
performed some preliminary experiments to address this possibil-
ity. We did not detect any changes in FGFR1 and FGFR3 mRNA
expression in UM-UC3 cells after knockdown of either ZEB1 or
SNAIL (data not shown), strongly suggesting that these canonical
EMT transcription factors are not involved in regulating their
expression. However, we did observe changes in several EMT
regulators in the UM-UC3 or UM-UC13 cells following
knockdown of FGFR1 (Fig. S6), consistent with the idea that
FGFR1 signaling functions upstream to drive EMT. Parallel
studies have implicated PLCc, ERK, and cyclooxygenase-2 in
FGFR1-mediated EMT in BC cells [11]. Defining the transcrip-
tional targets of FGFR1 responsible for mediating EMT will be an
important area for future research.
Supporting Information
Figure S1 Baseline expression of FGFR1, FGFR3 and bFGF proteins in
subsets of epithelial and mesenchymal human bladder cancer cells. Protein
levels in 3 representative ‘‘epithelial’’ (UM-UC14, RT4 and
RT112) and 3 ‘‘mesenchymal’’ (UM-UC3, UM-UC12 and UM-
UC13) cell lines were measured by immunoblotting.
(TIF)
Figure S2 Correlation between FGFR/bFGF expression and EMT
markers. The figure displays the results of the correlation analyses.
Correlation coefficients are displayed in red, and corresponding p
values are depicted in black. Negative correlation coefficients
indicate the presence of an inverse relationship between markers.
(TIF)
Figure S3 FGFR3 mutation status in human bladder cancer cells. The
presence of activating FGFR3 mutations was determined by
exome sequencing. Note that among the 5 cell lines within the
panel that contain activating mutations, only one (UM-UC14) is
sensitive to BGJ-398.
(TIF)
Figure S4 Effects of FGFR1 knockdown on FGFR1 expression and
proliferation in RT4 and UM-UC14 cells. A. Left panel: UM-UC14 or
RT4 cells were transiently transfected with either non-targeting
(NT) or FGFR1-specific siRNAs and cell growth was measured at
48 h using MTT. Mean 6 SEM, n= 8. Right Panel: the efficiency
of FGFR1 silencing by siRNA was determined by quantitative
RT-PCR. B. UM-UC14 or RT4 cells were transiently transfected
with either non-targeting (NT) or FGFR1-specific siRNAs and
percentages of cells within each phase of the cell cycle were
quantified by propidium iodide staining and FACS analysis. Mean
6 SEM, n= 3.
(TIF)
Figure S5 Effects of bFGF or FGFR1 knockdown in long-term assays. A.
MTT results obtained in 5-day assays. Mean 6 SEM, n= 6.
*p,0.05. B. Results obtained in soft agar colony formation assays.
The left panels display the numbers of colonies and the right
panels colony diameters as determined by measuring colony
growth in soft agar. Mean 6 SEM, n=5.
(TIF)
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Figure S6 Effects of bFGF or FGFR1 knockdown on EMT marker
expression. Mean 6 SEM, n= 3.
(TIF)
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